Cargando…

Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review

Two sets of response criteria using PET are currently available to monitor metabolic changes in solid tumors: the criteria developed by the European Organization for Research and Treatment of Cancer (EORTC criteria) and the PET Response Criteria in Solid Tumors (PERCIST). We conducted this pooled st...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kim, Jung Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295415/ https://www.ncbi.nlm.nih.gov/pubmed/27517621 http://dx.doi.org/10.18632/oncotarget.11171

Ejemplares similares

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
por: Lasnon, Charline, et al.
Publicado: (2017)

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022)

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

Response criteria in solid tumors (PERCIST/RECIST) and SUV(max) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
por: Pierson, Cory, et al.
Publicado: (2018)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article
por: Nakajo, Masatoyo, et al.
Publicado: (2021)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?
por: Bhoil, Amit
Publicado: (2023)

Factors That Affect PERCIST-Defined Test-Retest Comparability: An Exploration of Feasibility in Routine Clinical Practice
por: Yuan, Hui, et al.
Publicado: (2015)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
por: Vogsen, Marianne, et al.
Publicado: (2021)

A method for evaluation of patient-specific lean body mass from limited-coverage CT images and its application in PERCIST: comparison with predictive equation
por: Shang, Jingjie, et al.
Publicado: (2021)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT)
por: Gamper, Eva-Maria, et al.
Publicado: (2016)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
por: Khoshnevisan, Alireza, et al.
Publicado: (2012)

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)

The Assessment of Tumor Response by Measuring the Single Largest Lesion per Organ in Metastatic Tumors: A Pooled Analysis of Previously Reported Data
por: Jang, Hyun Joo, et al.
Publicado: (2015)

Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
por: van der Hage, Jos A, et al.
Publicado: (2011)

STatistically Assigned Response Criteria in Solid Tumors (STARCIST)
por: Bengtsson, Thomas, et al.
Publicado: (2015)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Comparison of the Diagnostic Performance of Response Evaluation Criteria in Solid Tumor 1.0 with Response Evaluation Criteria in Solid Tumor 1.1 on MRI in Advanced Breast Cancer Response Evaluation to Neoadjuvant Chemotherapy
por: Jeh, Su Kyung, et al.
Publicado: (2013)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria
por: Huang, Linna, et al.
Publicado: (2017)

Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer
por: Lai, Ming-Yu, et al.
Publicado: (2022)

Genomic Characterization and Comparison of Multi-Regional and Pooled Tumor Biopsy Specimens
por: Joung, Je-Gun, et al.
Publicado: (2016)

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria
por: Lanese, Andrea, et al.
Publicado: (2018)

Quantitation of cancer treatment response by 2-[(18)F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
por: O, Joo Hyun, et al.
Publicado: (2021)

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26
por: Sztankay, Monika, et al.
Publicado: (2018)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b10u5cd205lfr4g6nn8e3s6qcr